

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**PuraPharm**

**PURAPHARM CORPORATION LIMITED**

**培力農本方有限公司**

*(Formerly known as 培力控股有限公司 in Chinese)*

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1498)**

## **GRANT OF SHARE OPTIONS**

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Directors**”) of PuraPharm Corporation Limited (the “**Company**”) hereby announces that on 29 December 2022 the Board resolved to grant share options (the “**Options**”) to two Directors (the “**Grantees**”), subject to the acceptance of the Options and the payment of HK\$1 by each of the Grantees, entitling them to subscribe for a total of 7,700,000 ordinary shares of the Company (each a “**Share**”) under the share option scheme adopted on 12 June 2015. Details of the Options granted are set out below:

Date of grant	:	29 December 2022 (the “ <b>Date of Grant</b> ”)
Total number of Shares issuable under Options granted	:	7,700,000 Options, each Option shall entitle the holder of the Option to subscribe for one Share
Exercise price of the Options	:	HK\$1.29 per Share, which represents the highest of:  (i) the closing price of HK\$1.28 per Share as stated in the Stock Exchange’s daily quotation sheets on the Date of Grant;

(ii) the average closing price of HK\$1.29 per Share as stated in the Stock Exchange's daily quotation sheets for the five business days immediately preceding the Date of Grant; and

(iii) the nominal value of US\$0.1 per Share.

Closing price of the Options on the Date of Grant : HK\$1.28 per Share

Validity period of the Options : 10 years from the Date of Grant to 28 December 2032, both dates inclusive

Vesting schedule of the Options : 50% of Options granted shall be vested to the Grantees on the first anniversary date of grant and the remaining balance of 50% shall be vested to the Grantees on the second anniversary date of grant

The purposes of the grant of the Options are to retain high-calibre personnel, give incentive and reward the Grantees for their performance in the Company which may enhance the value of the Company and the Shares.

The above 7,700,000 Options were granted to the Directors of the Company, details of which are set out below:

<b>Name of Director</b>	<b>Position held with the Company</b>	<b>Number of Options granted</b>
Mr. Chan Yu Ling, Abraham	Executive Director and substantial shareholder	3,850,000
Ms. Man Yee Wai, Viola	Executive Director and substantial shareholder	3,850,000

As at the date of this announcement, Mr. Chan Yu Ling, Abraham and Ms. Man Yee Wai, Viola are the substantial shareholders of the Company.

The grant of the Options to the above Directors and the substantial shareholders has been approved by the independent non-executive Directors in accordance with Rule 17.04(1) of the Listing Rules.

Save as disclosed above, none of the Grantees is a Director, chief executive or substantial shareholder of the Company or any of their respective associates (as defined under the Listing Rules).

By order of the Board  
**PuraPharm Corporation Limited**  
**Chan Yu Ling, Abraham**  
*Chairman*

Hong Kong, 29 December 2022

*As at the date of this announcement, the executive Directors of the Company are Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola and Dr. Norimoto Hisayoshi; and the independent non-executive Directors of the Company are Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.*